ADBIOTECH Co.,Ltd. Logo

ADBIOTECH Co.,Ltd.

Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.

179530 | KO

Overview

Corporate Details

ISIN(s):
KR7179530001
LEI:
Country:
South Korea
Address:
강원도 춘천시 동내면 거두단지1길 39, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the research, development, manufacturing, and sale of next-generation immune antibodies. The company's core technology is based on Immunoglobulin Y (IgY), producing specific antibodies from eggs as alternatives to conventional vaccines and antibiotics. Its product portfolio serves diverse markets, including livestock, aquaculture, and human health, with commercialized products sold both domestically and internationally. ADBIOTECH is actively expanding its R&D pipeline to include human therapies, such as Helico IgY and Cholesterol IgY, and is entering the global companion animal market with its proprietary VHH (nanobody) technology. The company manages the entire value chain from research to production and sales, positioning itself as a leader in the IgY technology field.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 31.7 KB
2025-09-15 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 133.2 KB
2025-09-15 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 81.3 KB
2025-08-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 68.2 KB
2025-08-29 00:00
M&A Activity
[기재정정]경영권변경등에관한계약체결
Korean 17.2 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 105.4 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Korean 102.6 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 95.8 KB
2025-08-22 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 29.0 KB
2025-08-22 00:00
Pre-Annual General Meeting Information
[기재정정]주주명부폐쇄기간또는기준일설정
Korean 7.6 KB
2025-08-22 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 132.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 35.8 KB
2025-08-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 129.8 KB
2025-08-14 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 81.6 KB

Automate Your Workflow. Get a real-time feed of all ADBIOTECH Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ADBIOTECH Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ADBIOTECH Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.